First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate | Zendy

Romney M. Humphries | Zendy; Shangxin Yang | Zendy; Peera Hemarajata | Zendy; Kevin W. Ward | Zendy; Janet A. Hindler | Zendy; Shelley A. Miller | Zendy; Aric L. Gregson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

Author(s) -

Romney M. Humphries,

Shangxin Yang,

Peera Hemarajata,

Kevin W. Ward,

Janet A. Hindler,

Shelley A. Miller,

Aric L. Gregson

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01165-15

Subject(s) - ceftazidime/avibactam , klebsiella pneumoniae , avibactam , ceftazidime , microbiology and biotechnology , enterobacteriaceae , beta lactamase inhibitors , medicine , biology , antibiotics , bacteria , escherichia coli , pseudomonas aeruginosa , biochemistry , genetics , gene

Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research